Liquidia
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requir...
Latest News
2 days ago · seekingalpha.com
Liquidia: Yutrepia's PAH Franchise Has Room To GrowLiquidia kept the right to market YUTREPIA for PAH after the settlement with United Therapeutics. This settlement limits YUTREPIA's potential in PH-ILD, but since it can still be sold to patients using it and to patients with PAH, Liquidia Corporation can continue generating revenue. YUTREPIA is already generating cash. Paid PAH starts will show how much of the lost PH-ILD growth LQDA can replace.
5 days ago · zacks.com
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia SalesLiquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.
5 days ago · zacks.com
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement OutlookLiquidia reports surging YUTREPIA sales, record October shipments and expanding PAH adoption amid post-settlement market changes and referral disruptions.
6 days ago · marketbeat.com
Liquidia Q3 Earnings Call HighlightsLiquidia NASDAQ: LQDA reported a 31% sequential increase in third-quarter YUTREPIA sales as the company sought to reassure investors that its pulmonary arterial hypertension business can continue growing following a patent settlement with United Therapeutics.
6 days ago · seekingalpha.com
Liquidia Corporation (LQDA) Q3 2026 Earnings Call TranscriptLiquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript
6 days ago · zacks.com
Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat EstimatesLiquidia Corporation (LQDA) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to a loss of $0.04 per share a year ago.
6 days ago · globenewswire.com
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare ConferenceMORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company's business in a fireside chat at the 2026 Jefferies Global Healthcare Conference, Tuesday, November 17, at 10 a.m.
6 days ago · globenewswire.com
Liquidia Corporation Reports Third Quarter 2026 Financial ResultsMORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the third quarter ended September 30, 2026. The company will also host a webcast at 8:30 a.m. ET on November 10, 2026, to discuss its financial results and provide a corporate update.
14 days ago · globenewswire.com
Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its third quarter 2026 financial results on Tuesday, November 10, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
20 days ago · zacks.com
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove LQDA